AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nuo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026
- Market cap
- $60.99M
- P/E (TTM)
- –
- Dividend yield
- –
Nuo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $3.09M | $1.37M | $608.53K | $112.25K | $0 | $0 | $146.18K | $332.44K | $530.94K | – | 93.2% | +126.2% |
| Aurix and Private Label Kits [Member] | $1.23M | – | – | – | – | – | – | – | – | – | 37.0% | – |
| License [Member] | $225.00K | $0 | – | – | – | – | – | $750.00K | – | – | 6.8% | – |
| Aurix and Private Label Centrifuge Devices [Member] | $77.00K | – | – | – | – | – | – | – | – | – | 2.3% | – |
| Royalty [Member] | – | – | – | – | – | – | – | $288.16K | $190.11K | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | – | – | $5.46M | – | – |
| Non-US [Member] | – | – | – | – | – | – | – | – | – | $930.66K | – | – |
From the segment and revenue-disaggregation notes of Nuo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.